GB201905105D0 - Formulations - Google Patents

Formulations

Info

Publication number
GB201905105D0
GB201905105D0 GBGB1905105.1A GB201905105A GB201905105D0 GB 201905105 D0 GB201905105 D0 GB 201905105D0 GB 201905105 A GB201905105 A GB 201905105A GB 201905105 D0 GB201905105 D0 GB 201905105D0
Authority
GB
United Kingdom
Prior art keywords
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1905105.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunocore Ltd
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Priority to GBGB1905105.1A priority Critical patent/GB201905105D0/en
Publication of GB201905105D0 publication Critical patent/GB201905105D0/en
Priority to DK20701703.9T priority patent/DK3911298T3/en
Priority to SI202030360T priority patent/SI3911298T1/en
Priority to BR112021014031-0A priority patent/BR112021014031A2/en
Priority to CN202080022368.1A priority patent/CN113645953A/en
Priority to HRP20240176TT priority patent/HRP20240176T1/en
Priority to PL20701703.9T priority patent/PL3911298T3/en
Priority to KR1020217025022A priority patent/KR20210116513A/en
Priority to PCT/EP2020/051002 priority patent/WO2020148372A1/en
Priority to EP23187615.2A priority patent/EP4279082A3/en
Priority to CA3126611A priority patent/CA3126611A1/en
Priority to EP20701703.9A priority patent/EP3911298B1/en
Priority to MX2021008578A priority patent/MX2021008578A/en
Priority to AU2020209991A priority patent/AU2020209991A1/en
Priority to US17/423,843 priority patent/US20220080030A1/en
Priority to PT207017039T priority patent/PT3911298T/en
Priority to LTEPPCT/EP2020/051002T priority patent/LT3911298T/en
Priority to FIEP20701703.9T priority patent/FI3911298T3/en
Priority to JP2021541283A priority patent/JP2022523290A/en
Priority to RS20240138A priority patent/RS65139B1/en
Priority to IL284691A priority patent/IL284691A/en
Ceased legal-status Critical Current

Links

GBGB1905105.1A 2019-01-17 2019-04-10 Formulations Ceased GB201905105D0 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GBGB1905105.1A GB201905105D0 (en) 2019-04-10 2019-04-10 Formulations
RS20240138A RS65139B1 (en) 2019-01-17 2020-01-16 Formulations
CA3126611A CA3126611A1 (en) 2019-01-17 2020-01-16 Formulations
MX2021008578A MX2021008578A (en) 2019-01-17 2020-01-16 Formulations.
BR112021014031-0A BR112021014031A2 (en) 2019-01-17 2020-01-16 PHARMACEUTICAL FORMULATION, USE OF FORMULATION, AND METHOD OF PREPARING AN AQUEOUS PHARMACEUTICAL FORMULATION
CN202080022368.1A CN113645953A (en) 2019-01-17 2020-01-16 Preparation
HRP20240176TT HRP20240176T1 (en) 2019-01-17 2020-01-16 Formulations
PL20701703.9T PL3911298T3 (en) 2019-01-17 2020-01-16 Formulations
KR1020217025022A KR20210116513A (en) 2019-01-17 2020-01-16 formulation
PCT/EP2020/051002 WO2020148372A1 (en) 2019-01-17 2020-01-16 Formulations
EP23187615.2A EP4279082A3 (en) 2019-01-17 2020-01-16 Formulations
DK20701703.9T DK3911298T3 (en) 2019-01-17 2020-01-16 FORMULATIONS
EP20701703.9A EP3911298B1 (en) 2019-01-17 2020-01-16 Formulations
SI202030360T SI3911298T1 (en) 2019-01-17 2020-01-16 Formulations
AU2020209991A AU2020209991A1 (en) 2019-01-17 2020-01-16 Formulations
US17/423,843 US20220080030A1 (en) 2019-01-17 2020-01-16 Formulations
PT207017039T PT3911298T (en) 2019-01-17 2020-01-16 Formulations
LTEPPCT/EP2020/051002T LT3911298T (en) 2019-01-17 2020-01-16 Formulations
FIEP20701703.9T FI3911298T3 (en) 2019-01-17 2020-01-16 Formulations
JP2021541283A JP2022523290A (en) 2019-01-17 2020-01-16 pharmaceutical formulation
IL284691A IL284691A (en) 2019-01-17 2021-07-07 Formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1905105.1A GB201905105D0 (en) 2019-04-10 2019-04-10 Formulations

Publications (1)

Publication Number Publication Date
GB201905105D0 true GB201905105D0 (en) 2019-05-22

Family

ID=66809467

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1905105.1A Ceased GB201905105D0 (en) 2019-01-17 2019-04-10 Formulations

Country Status (1)

Country Link
GB (1) GB201905105D0 (en)

Similar Documents

Publication Publication Date Title
IL287224A (en) Novel formulations comprising melflufen
GB201707189D0 (en) Novel formulations
GB201707188D0 (en) Novel formulations
GB201809976D0 (en) Novel formulations
GB201904338D0 (en) Fluorouracil-containing formulations
IL284688A (en) Formulation
PT4045038T (en) New formulations
IL290356A (en) Larazotide formulations
IL284691A (en) Formulations
GB201707187D0 (en) Novel formulations
GB202018889D0 (en) Formulations
GB202009684D0 (en) Formulations
GB201913232D0 (en) Aerosolisable formulation
SG11202010097WA (en) Apixaban formulations
GB201911063D0 (en) Formulations
GB201905105D0 (en) Formulations
GB201910093D0 (en) New formulations
GB201910092D0 (en) New formulations
SG11202011823SA (en) Activator-nucleator formulations
GB201819028D0 (en) Butanol-based formulations
GB2587402B (en) Formulation
GB201808386D0 (en) Formulations
GB201804545D0 (en) Formulations
GB201803201D0 (en) Formulations
GB202115121D0 (en) Formulations

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)